Aggressive salvage treatment is not appropriate for the majority of elderly patients with acute myeloid leukemia relapsing after first complete remission

Haematologica

Volumn 86, Issue 8, 2001, Pages 814-820

  Ferrara, F ^a   Morabito, F ^a   Latagliata, R ^a   Martino, B ^a   Annunziata, M ^a   Oliva, E ^a   Schiavone, M E ^a   Pollio, F ^a   Palmieri, S ^a   Gianfaldoni, G ^a   Leoni, F ^a  

^a NONE   (Italy)

Author keywords

Acute myeloid leukemia; Elderly patients; Relapse

Indexed keywords

CYTARABINE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; ELDERLY CARE; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PALLIATIVE THERAPY; PROGNOSIS; SALVAGE THERAPY; TREATMENT OUTCOME;

ACUTE DISEASE; AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0034858045     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Estimate of overall treatment results in acute nonlymphocytic leukemia based on age-specific rates of incidence and of complete remission
2. Acute myelogenous leukaemia in the elderly: Retrospective study of 235 consecutive patients
3. Age distribution and hemogram analysis of the 4496 cases recorded during 1982-1983 and classified according to FAB criteria
4. De novo acute myeloid leukaemia in patients over 55-years-old: A population-based study of incidence, treatment and outcome
5. Treatment of elderly patients with AML: Results of an individualized approach
6. Treatment of the elderly patient with acute myeloid leukaemia
7. How I treat older patients with AML
8. Acute myeloid leukemia in the elderly: A critical review of therapeutic approaches and appraisal of results of therapy
9. Management of acute myeloid leukemia in elderly patients
10. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: A Southwest Oncology Group Study
11. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy
12. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia
13. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490)
14. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study (9031)
15. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients
16. Acute myeloid leukemia in the elderly: "Per aspera ad astra"?
17. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group
18. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy
19. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation
20. Non parametric estimation from incomplete observation
21. Regression models and life-tables
22. Treatment of relapsed and refractory acute myelogenous leukemia
23. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia
24. Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: A pharmacologically based regimen
25. The characteristics and outcome of patients with late relapse acute myelogenous leukemia
26. Prognostic factors at relapse for adults with acute myeloid leukemia
27. The management of recurrent acute myelogenous leukaemia at a single centre over a fifteen-year period
28. Duration of second complete remission compared with first complete remission in patients with acute myeloid leukemia
29. Prognostic significance of karyotype in de novo adult acute myeloid leukemia
30. Intensive treatment of patients age 60 years and older with de novo acute myeloid leukemia: Analysis of prognostic factors
31. Serum LDH value as a predictor of clinical outcome in acute myelogenous leukaemia of the elderly
32. Therapeutic options and treatment results for patients over 75 years of age with acute myeloid leukemia
33. Reversal of multidrug resistance in hematological malignancies
34. Malignant progenitors from patients with acute myelogenous leukemia are sensitive to a diphtheria toxin-granulocyte-macrophage colony-stimulating factor fusion protein
35. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses
36. Polyethylene glycolated interleukin-2 as maintenance therapy for acute myelogenous leukemia in second remission
37. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate
38. Current use of monoclonal antibodies in the treatment of acute leukemia
39. New approaches to treating malignancies with stem cell transplantation